Who is sponsoring NCT03907670?

NCT03907670 is sponsored by Assiut University.

What condition does NCT03907670 study?

NCT03907670 studies Chronic Phase Chronic Myelogenous Leukemia.

Is NCT03907670 still recruiting?

NCT03907670 is currently status unknown. Last updated 30 September 2019.

Last reviewed 2019-09-30 · How we verify

NCT03907670

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor

Status unknown Last updated 30 September 2019

What this trial tests

trial in Chronic Phase Chronic Myelogenous Leukemia in 45 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
1 October 2020

1 October 2021

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	45
Start date	1 October 2019
Primary completion	1 October 2020
Estimated completion	1 October 2021

Conditions studied

Chronic Phase Chronic Myelogenous Leukemia — all drugs for Chronic Phase Chronic Myelogenous Leukemia →

Sponsor

Assiut University

Who can join

Adults 20 to 80, any sex, with Chronic Phase Chronic Myelogenous Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to assesse the levels of various biomarkers, specifically interleukin (IL)-6, platelet-derived microparticles (PDMPs), 11, 12 soluble vascular cell adhesion molecule 1 (sVCAM-1), transforming growth factor (TGF) β1, and sCTLA-4, in TKI-treated patients with CML. To measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML..

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Phase Chronic Myelogenous Leukemia

Currently open trials in the same condition.

NCT05007873 — ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid L · Phase 2 · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03907670 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 30 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03907670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing